Gershenson DM - Search Results

1

Antiangiogenic and antitumor effects of SRC inhibition in ovarian carcinoma.

Han LY, Landen CN, Trevino JG, Halder J, Lin YG, Kamat AA, Kim TJ, Merritt WM, Coleman RL, Gershenson DM, Shakespeare WC, Wang Y, Sundaramoorth R, Metcalf CA 3rd, Dalgarno DC, Sawyer TK, Gallick GE, Sood AK. Han LY, et al. Among authors: gershenson dm. Cancer Res. 2006 Sep 1;66(17):8633-9. doi: 10.1158/0008-5472.CAN-06-1410. Cancer Res. 2006. PMID: 16951177 Free PMC article.

2

Mucinous carcinoma of the ovary. Pathologic prognostic factors.

Watkin W, Silva EG, Gershenson DM. Watkin W, et al. Among authors: gershenson dm. Cancer. 1992 Jan 1;69(1):208-12. doi: 10.1002/1097-0142(19920101)69:1<208::aid-cncr2820690134>3.0.co;2-k. Cancer. 1992. PMID: 1309304

3

The long-term effects of radiation therapy on patients with ovarian dysgerminoma.

Mitchell MF, Gershenson DM, Soeters RP, Eifel PJ, Delclos L, Wharton JT. Mitchell MF, et al. Among authors: gershenson dm. Cancer. 1991 Feb 15;67(4):1084-90. doi: 10.1002/1097-0142(19910215)67:4<1084::aid-cncr2820670436>3.0.co;2-e. Cancer. 1991. PMID: 1991256

4

Serous ovarian tumors of low malignant potential with peritoneal implants.

Gershenson DM, Silva EG. Gershenson DM, et al. Cancer. 1990 Feb 1;65(3):578-85. doi: 10.1002/1097-0142(19900201)65:3<578::aid-cncr2820650332>3.0.co;2-n. Cancer. 1990. PMID: 2297647

5

Transitional cell carcinoma in high-grade high-stage ovarian carcinoma. An indicator of favorable response to chemotherapy.

Robey SS, Silva EG, Gershenson DM, McLemore D, el-Naggar A, Ordonez NG. Robey SS, et al. Among authors: gershenson dm. Cancer. 1989 Mar 1;63(5):839-47. doi: 10.1002/1097-0142(19890301)63:5<839::aid-cncr2820630508>3.0.co;2-u. Cancer. 1989. PMID: 2644014

6

Salvage chemotherapy for refractory transitional cell carcinoma of the ovary (TCC).

Sweeten KM, Gershenson DM, Burke TW, Morris M, Levenback C, Silva EG. Sweeten KM, et al. Among authors: gershenson dm. Gynecol Oncol. 1995 Nov;59(2):211-5. doi: 10.1006/gyno.1995.0010. Gynecol Oncol. 1995. PMID: 7590475

7

Surgical therapy of T1 and T2 vulvar carcinoma: further experience with radical wide excision and selective inguinal lymphadenectomy.

Burke TW, Levenback C, Coleman RL, Morris M, Silva EG, Gershenson DM. Burke TW, et al. Among authors: gershenson dm. Gynecol Oncol. 1995 May;57(2):215-20. doi: 10.1006/gyno.1995.1128. Gynecol Oncol. 1995. PMID: 7729737 Clinical Trial.

8

Update on malignant ovarian germ cell tumors.

Gershenson DM. Gershenson DM. Cancer. 1993 Feb 15;71(4 Suppl):1581-90. doi: 10.1002/cncr.2820710425. Cancer. 1993. PMID: 8381708 Review.

9

Infusion site soft-tissue injury after paclitaxel administration.

Bicher A, Levenback C, Burke TW, Morris M, Warner D, DeJesus Y, Gershenson DM. Bicher A, et al. Among authors: gershenson dm. Cancer. 1995 Jul 1;76(1):116-20. doi: 10.1002/1097-0142(19950701)76:1<116::aid-cncr2820760118>3.0.co;2-p. Cancer. 1995. PMID: 8630862

10

Ovarian serous borderline tumors with invasive peritoneal implants.

Gershenson DM, Silva EG, Levy L, Burke TW, Wolf JK, Tornos C. Gershenson DM, et al. Cancer. 1998 Mar 15;82(6):1096-103. Cancer. 1998. PMID: 9506355

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

509 results

Search Page